Last reviewed · How we verify
NCT05104424: COVID-19
The Study of Quadruple Therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation for Post COVID-19 Smell and Taste Dysfunctions
Phase 1 trial testing Insulin aspart in Smell Dysfunction in 22 participants. Status unknown.
26 August 2022
Quick facts
| Lead sponsor | Ministry of Health, Saudi Arabia |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 26 December 2021 |
| Primary completion | 26 August 2022 |
| Estimated completion | 1 October 2022 |
Drugs / interventions tested
- Insulin aspart (INSULIN ASPART) — full drug profile →
Conditions studied
- Smell Dysfunction — all drugs for Smell Dysfunction →
- Taste Disorders — all drugs for Taste Disorders →
- Taste Disorder, Secondary, Sweet — all drugs for Taste Disorder, Secondary, Sweet →
- Taste Disorder, Secondary, Bitter — all drugs for Taste Disorder, Secondary, Bitter →
Sponsor
Ministry of Health, Saudi Arabia
Who can join
Adults 18 to 75, any sex, with Smell Dysfunction or Taste Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
post covid-19 smell and taste dysfunction are common globally and affect the quality of life and also have phycological impact and anxiety, also affect on economy as the patients not able to do cooking or buy prepared foods and not eaten, also not able to enter the cooking room and prepare foods for themselves, also the risk of loss of smell the fire accidents because anosmia, many forms of smell dysfunction like anosmia ,hyposmia, and dysosmia ,Phantosmia , parosmia may occurred, the same taste disorders may has many forms like Dysgeusia, phantom taste perception, hypogeusia with dysgeusia. until now no definite treatments for post covid-19 smell and taste disorders , this study is novel study as quadruple therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation may suspect having promising results
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics.
Leng A, Shah M, Ahmad SA, Premraj L, et al · · 2023 · cited 124× · PMID 36899952 · DOI 10.3390/cells12050816 -
Clinical trials on the pharmacological treatment of long COVID: A systematic review.
Chee YJ, Fan BE, Young BE, Dalan R, et al · · 2023 · cited 55× · PMID 36349400 · DOI 10.1002/jmv.28289 -
Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents.
Imran M, Fatima W, Alzahrani AK, Suhail N, et al · · 2022 · cited 13× · PMID 35334884 · DOI 10.3390/nu14061227
Verify or expand the search:
- PubMed search for NCT05104424
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Insulin aspart
Trials testing the same drug.
- NCT07076199 — A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insuli · Phase 3 · recruiting
- NCT06809621 — A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insul · Phase 1 · completed
- NCT05946798 — Role of NADPH Oxidase in Microvascular Dysfunction Following GDM · EARLY_PHASE1 · recruiting
- NCT06127433 — The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucos · Phase 4 · unknown
- NCT04880850 — A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, I · Phase 3 · completed
Other recruiting trials for Smell Dysfunction
Currently open trials in the same condition.
- NCT07309341 — Effects of Isotretinoin on Smell · NA · recruiting
- NCT07021040 — Olfactory Biopsies · NA · recruiting
- NCT05855369 — Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID) · Phase 2, PHASE3 · recruiting
- NCT06456008 — Prospective Registery of Smell/Taste Clinic Ear/Nose/Throat · recruiting
- NCT05364125 — Olfactory Training on Smell Dysfunction Patients in HK · NA · recruiting
Other Ministry of Health, Saudi Arabia trials
Trials by the same sponsor.
- NCT06057077 — Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus · Phase 1, PHASE2 · unknown
- NCT05957939 — Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial · Phase 1 · unknown
- NCT06026163 — Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress · Phase 2, PHASE3 · recruiting
- NCT06071338 — A Decision Support System Based on Classification Algorithms for the Diagnosis of Periodontal Disease · unknown
- NCT05680662 — The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Can · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05104424 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ministry of Health, Saudi Arabia
- Last refreshed: 3 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05104424.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing